<DOC>
	<DOCNO>NCT01995227</DOCNO>
	<brief_summary>The purpose study determine safety immunological , radiological , pathological response personalize anti-cancer vaccine AlloVax ( TM ) patient refractory Hepatocellular Carcinoma ( HCC ) eligible approve HCC treatment fail approved HCC treatment . AlloVax ( TM ) personalize anti-cancer vaccine combine Chaperone Rich Cell Lysate ( CRCL ) source tumor antigen prepare patient 's tumor AlloStim ( TM ) adjuvant . The combination two component provide vaccine design bring immune response capable find kill tumor cell .</brief_summary>
	<brief_title>An Individualized Anti-Cancer Vaccine Study Patients With HCC</brief_title>
	<detailed_description>All accrue subject undergo tumor harvest procedure . The tumor sample process personalized Chaperone Rich Cell Lysate ( CRCL ) vaccine . This study consist three phase : priming phase , vaccination phase , activation phase . The prim phase involve intradermal injection AlloStim ( TM ) . The aim phase increase titer Th1 immune cell circulation . The vaccination phase involve intradermal injection AlloSim ( TM ) immediately follow intradermal injection CRCL . This phase design elicit tumor-specific immunity . The activation phase involve intravenous infusion AlloStim ( TM ) . This phase design activate memory cell NK cell cause extravasate traffic tumor site .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Any Patients diagnosis HCC base histology current accept radiological measure . Age &gt; 18 year . Patient MRI CT result ( positive HCC ) 3 month prior recruitment . AFP &gt; 30 . Patient eligible fail approved HCC treatment . Patient unable unwilling sign inform consent . Patients participate clinical trial evaluate experimental treatment procedure . Severe congestive heart failure ( LVEF echocardiogram &lt; 20 % ) . Severe pulmonary hypertension ( By echocardiogram , PAS &gt; 45 mmHg ) . Uncontrolled diabetes mellitus ( HBA1C &gt; 9.5 % ) . Any autoimmune disorder , currently treat prednisone immune suppressive medication . Patients currently receive total parenteral nutrition contraindication oral drug . Patients positive HIV1 , HIV2 , HTLV1 , HTLV2 , RPR ( syphilis ) . Women pregnant breast feeding . Patients , base opinion investigator , enrol study . HBV DNA positive . If patient HBsAg positive HBcAB positive , HBV DNA negative , irrespective his/her antiHBS status , patient enrol , receive preemptive therapy Lamivudine . Patients HBV DNA positive enroll , turn negative therapy enrol . Patients HBV HCV follow HBV DNA HCV RNA level trial . Any metastasis except portal vein involvement . Patients Child Pugh B8 . Prior experimental therapy cancer vaccine treatment ( e.g. , dendritic cell therapy , heat shock vaccine ) . History blood transfusion reaction . Known allergy bovine murine product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>liver cancer</keyword>
	<keyword>HCC</keyword>
	<keyword>tumor vaccine</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>personalize anti-cancer vaccine</keyword>
</DOC>